Monthly injection may ease anemia treatment for kidney patients

NCT ID NCT07025460

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 4 study tested whether a once-monthly injection of darbepoetin alfa works as well as the standard every-2-week schedule for maintaining healthy hemoglobin levels in people with advanced chronic kidney disease who are not on dialysis. Forty Korean adults completed the 12-week evaluation phase. The goal was to see if the monthly dosing could keep hemoglobin at or above 10.0 g/dL, which would mean fewer injections and less burden for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
darbepoetin alfa
What this could lead to
If successful, this could offer a more convenient once-monthly injection schedule for managing anemia in chronic kidney disease, potentially improving patient adherence and reducing healthcare visits.
What could go wrong
This is a small, single-arm study in a specific Korean population, so results may not apply broadly. The trial is already complete, and while it showed non-inferiority, larger studies would be needed to confirm safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.